B., Drmic, D., Grgic, T., Strbe, S., Zukanovic, G., Crvenkovic, D., Madzarac, G., Rukavina, I., Sucic, M., Baric, M., Starcevic, N., Krstonijevic, Z., Bencic, M
Coevolution of URAT1 and uricase during primate evolution: implications for serum urate homeostasis and gout
A new clinical trial, co-led by endocrinologist and diabetes expert John Buse, MD, PhD, and interventional cardiologist Matthew Cavender, MD, MPH, at the UNC School of Medicine has shown that the oral form of semaglutide can significantly reduce cardiovascular events in people with type 2 diabetes and atherosclerotic cardiovascular disease, and/or chronic kidney disease
Proper rotation prevents complications that can genuinely undermine semaglutide effectiveness
According to Antlerzz, online searches for the GLP-1 semaglutide injection, which was originally intended for type 2 diabetes management, rose 170% in the U.S